Patents by Inventor Gillian A. Kingsbury

Gillian A. Kingsbury has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
    Publication number: 20060216727
    Abstract: The invention provides isolated TANGO 239, TANGO 219, TANGO 232, TANGO 281, A236 (INTERCEPT 236), TANGO 300, TANGO 353, TANGO 393, TANGO 402, TANGO 351 and TANGO 509 nucleic acid molecules and polypeptide molecules. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: November 23, 2005
    Publication date: September 28, 2006
    Inventors: Douglas Holtzman, John Sharp, Kevin Leiby, Steven Bossone, Yang Pan, Thomas Barnes, Christopher Fraser, Nicholas Wrighton, Paul Myers, Gillian Kingsbury
  • Nucleic acid encoding human tango 509
    Patent number: 7041474
    Abstract: The invention provides isolated TANGO 239, TANGO 219, TANGO 232, TANGO 281, A236 (INTERCEPT 236), TANGO 300, TANGO 353, TANGO 393, TANGO 402, TANGO 351 and TANGO 509 nucleic acid molecules and polypeptide molecules. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: March 1, 2001
    Date of Patent: May 9, 2006
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Gillian Kingsbury
  • Glycoprotein VI antibodies and uses thereof
    Patent number: 6989144
    Abstract: The invention provides isolated nucleic acid molecules and polypeptide molecules that encode glycoprotein V1, a platelet membrane glycoprotein that is involved platelet-collagen interactions. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the exposure vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: June 30, 2000
    Date of Patent: January 24, 2006
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Samatha J. Busfield, Jean-Luc Villeval, Martine Jandrot-Perrus, William Vainchencker, Davinder Singh Gill, Ming Diana Qian, Gillian Kingsbury
  • Compositions and methods for the diagnosis and treatment of immune disorders
    Publication number: 20020058800
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. In particular, the invention describes a gene known in the art, alternatively, as ST2, T1 and Fit-1, and referred to herein as the 103 gene. The 103 gene is disclosed herein to be differentially expressed in TH2 cells and not in TH1 cells. Further, the 103 gene product is demonstrated herein to be an important modulator of TH2 and TH2-like immune response both in vitro and in vivo. Thus, the 103 gene, its gene products and antibodies that specifically bind thereto can be used diagnostically or as targets for therapeutic intervention in the treatment of a variety of immune disorders.
    Type: Application
    Filed: July 6, 2001
    Publication date: May 16, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Gillian A. Kingsbury, Kevin R. Leiby
  • Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
    Publication number: 20020055139
    Abstract: The invention provides isolated TANGO 239, TANGO 219, TANGO 232, TANGO 281, A236 (INTERCEPT 236), TANGO 300, TANGO 353, TANGO 393, TANGO 402, TANGO 351 and TANGO 509 nucleic acid molecules and polypeptide molecules. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: March 1, 2001
    Publication date: May 9, 2002
    Inventors: Douglas A. Holtzman, John D. Sharp, Kevin R. Leiby, Steven Bossone, Yang Pan, Thomas M. Barnes, Christopher C. Fraser, Nicholas Wrighton, Paul S. Myers, Gillian Kingsbury
  • Nucleic acid molecules encoding a 103 gene product and uses therefor
    Patent number: 6323334
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. In particular, the invention provides a nucleotide sequence which encodes a previously unknown human 103 gene product. The invention also provides expression vectors containing the nucleic acid molecules of the invention and host cells into which the expression vectors have been introduced. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: November 27, 2001
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Gillian A. Kingsbury, Kevin R. Leiby